MLI Making the Move to Once-Weekly Basal Insulin: Bridging Evidence and Everyday Care to Simplify Diabetes Management
This educational initiative focuses on empowering HCPs to optimize individualized care for patients with Type 2 diabetes (T2D). The interactive Real Answers to Real Questions format will integrate extensive peer-to-peer discussion into didactic presentation elements and provide clinicians with the opportunity to examine the latest clinical data and scientific advancements related to once-weekly basal insulins poised to enter the treatment armamentarium for this disease. By tackling real-world, practical questions that clinicians face every day, the activity will enhance HCPs’ confidence in the application of novel weekly basal insulins in routine practice when they become available, ultimately advancing equitable, patient-centered outcomes in T2D care.
Cost: Free
View Offer chevron_rightKey Features
This interactive activity explores emerging once-weekly basal insulins for T2D through expert-led presentations and peer-to-peer discussion. Key features include the latest clinical data, real-world implementation strategies, practical treatment considerations, and approaches to support individualized, equitable, patient-centered diabetes care.
Topics Covered
- Type 2 diabetes
- Diabetes
- T2D
- Obesity
- Weekly basal insulins
Learning Objectives
After completing this activity, the participant should be better able to:
- Compare the mechanisms and pharmacokinetic/pharmacodynamic properties of once-weekly and once-daily basal insulins to anticipate their potential clinical use
- Interpret the efficacy and safety data for emerging once-weekly basal insulins and apply this knowledge to anticipate their potential role in managing type 2 diabetes
- Develop individualized evidence-based treatment plans for patients with type 2 diabetes who require basal insulin that incorporates best practices for initiation, dosing, and titration
Target Audience
This activity is designed for primary care physicians, nurse practitioners, and physician associates who care for patients with T2D in the United States.
Additional credit info
1.0 AAFP, AAPA, ABIM MOC, ACCME, ANCC, IPCE
This activity is provided by ACOFP and MLI
In support of improving patient care, Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Osteopathic Physician Continuing Medical Education
The American College of Osteopathic Family Physicians (ACOFP) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians.
ACOFP designates this enduring activity for a maximum of 1.0 AOA Category 1-A credit and will report continuing medical education (CME) credits commensurate with the physician’s participation in this program.
Allopathic Physician Continuing Medical Education
Medical Learning Institute Inc (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.
Notice to Diplomates: MLI will report any claimed MOC/Lifelong Learning points to the appropriate Board within 4 weeks of completing the activity. Please ensure that you have provided your Board ID number and MMDD of birth.
AAFP CME Credit
The AAFP has reviewed Making the Move to Once-Weekly Basal Insulin: Bridging Evidence and Everyday Care to Simplify Diabetes Management and deemed it acceptable for up to 1.0 Enduring Materials, Self-Study AAFP Prescribed credit(s). Term of Approval is from 06/24/2026 to 06/23/2027. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PA
Medical Learning Institute Inc has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until June 23, 2027. PAs should only claim credit commensurate with the extent of their participation.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 1.0 contact hour in the area of pharmacology.
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
MIPS
Completion of this accredited CE activity will meet the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).
Support Statement
This activity is supported by an educational grant from Lilly.